Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...

The ASX 200 healthcare stock received another FDA approval for its cancer detection product. The post Up 113% in a year, ...

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) ...

And just today Telix announced another FDA approval for its Gozellix label, praised in the update as "Telix's next generation PSMA-PET imaging agent for prostate cancer." Gozellix is indicated for ...

Telix continued to deliver on its growth strategy ... Prepared for launch of three new products TLX007-CDx (Gozellix®), TLX101-CDx (Pixclara®) and TLX250-CDx (Zircaix®)4 in 2025 while ...